Anixa Biosciences, Inc. (ANIX)
| Market Cap | 72.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.60M |
| Shares Out | 32.01M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,295 |
| Open | 2.220 |
| Previous Close | 2.220 |
| Day's Range | 2.160 - 2.310 |
| 52-Week Range | 2.150 - 5.130 |
| Beta | 0.85 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+208.37%) |
| Earnings Date | Jun 4, 2024 |
About ANIX
Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer " primarily triple negative breast cancer (TNBC), the letha... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ANIX stock is "Strong Buy" and the 12-month stock price forecast is $7.0.
News
Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial
This patient is expected to be the final patient in the second dosage cohort of the trial SAN JOSE, Calif. , June 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: A...
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
Novel and proprietary CAR-T approach holds potential to be first effective CAR-T therapy for solid tumors SAN JOSE, Calif. , May 21, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Compa...
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
– Company currently collaborates with Cleveland Clinic on breast cancer and ovarian cancer vaccines – SAN JOSE, Calif., May 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (...
Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja
Dr. Amit Kumar interviewed in latest episode, 'The Vaccine That Could End Breast Cancer' SAN JOSE, Calif., May 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX)...
Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024
SAN JOSE, Calif., April 30, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of ca...
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
SAN JOSE, Calif., April 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of ca...
Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
SAN JOSE, Calif., March 14, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of ca...
Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
SAN JOSE, Calif., March 11, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of ca...
Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial
Dose escalation for fourth patient follows successful completion of first cohort SAN JOSE, Calif. , Feb. 12, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a c...
Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
Conference Investment Track spotlights promising and emerging biotech and healthcare companies advancing the field of oncology SAN JOSE, Calif. , Jan. 29, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ...
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
Broad coverage extended to Japan and related regions SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology c...
Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024
SAN JOSE, Calif. , Jan. 10, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of ca...
Anixa Biosciences to Present at Biotech Showcase 2024
SAN JOSE, Calif. , Dec. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of ca...
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
– Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T cell activation, increased over time from baseline – – Vaccine was safe and wel...
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
– Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – Conference call to commence at 6:30 p.m.
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology
SAN JOSE, Calif. , Nov. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...
Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference
Company to present on its ongoing Phase 1 ovarian cancer CAR-T trial SAN JOSE, Calif. , Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology...
Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board
SAN JOSE, Calif. , Oct. 23, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...
Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial
- With no dose-limiting toxicities observed, treatment of second dose cohort to begin SAN JOSE, Calif. , Oct. 13, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX)...
Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
SAN JOSE, Calif. , Oct. 3, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today anno...
Anixa Biosciences Establishes Cancer Business Advisory Board
SAN JOSE, Calif. , Sept. 19, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an...
Anixa Biosciences to Participate in September Investor Conferences
SAN JOSE, Calif. , Aug. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...
Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial
SAN JOSE, Calif. , Aug. 28, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an...
Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit
SAN JOSE, Calif. , Aug. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann...
Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
SAN JOSE, CA / ACCESSWIRE / August 10, 2023 / Cancer is a disease that affects millions of people around the world. Historically, cancer vaccines have not been very successful in treating or preventin...